GDMT for Heart Failure: The Four Pillars Every Hospitalist Should Know

GDMT for Heart Failure: Why the Four Pillars Matter

Heart failure is one of the most common conditions encountered by Hospitalists and Internal Medicine physicians.

For patients with heart failure with reduced ejection fraction (HFrEF), treatment has changed dramatically.

The modern approach is no longer:

Start one medication. Increase it to the maximum dose. Then consider another medication months later.

Today’s strategy emphasizes establishing the major disease-modifying therapies early, then optimizing them as tolerated.

This approach is commonly described as the:

Four Pillars of GDMT

For HFrEF, the foundational medication classes are:

1. ARNI — or ACE inhibitor/ARB when appropriate

2. Evidence-based beta-blocker

3. Mineralocorticoid receptor antagonist (MRA)

4. Sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor)

Together, these therapies form the foundation of modern HFrEF management.

For Hospitalists, there is another important message:

The hospitalization can be an opportunity to start building GDMT—not simply treat congestion and defer everything to the outpatient setting.

What Does GDMT Mean?

GDMT stands for:

Guideline-Directed Medical Therapy

It refers to medical therapies supported by clinical evidence and recommended by professional guidelines for a particular disease.

In heart failure, GDMT is especially important because several medications have demonstrated meaningful improvements in outcomes.

The goal isn’t simply to make the patient feel better today.

The broader goal is to:

Reduce heart-failure hospitalization
Reduce cardiovascular events
Improve symptoms
Improve quality of life
Slow disease progression
Improve survival when supported by the evidence for that therapy and population
First, Know the Heart-Failure Phenotype

Before discussing GDMT, clinicians need to identify the patient’s ejection-fraction category.

HFrEF

LVEF ≤40%

This is where the traditional four-pillar GDMT strategy is best established.

HFmrEF

LVEF 41–49%

Evidence-based therapy is also increasingly important in this group, particularly SGLT2 inhibitors.

HFpEF

LVEF ≥50%

Treatment differs from classic HFrEF GDMT. SGLT2 inhibitors have become an important evidence-based therapy, while management also focuses heavily on congestion and comorbidities.

HFimpEF

Some patients previously had HFrEF but later demonstrate improvement in LVEF above 40%.

An improved ejection fraction does not necessarily mean the underlying heart-failure biology has disappeared.

In general, HFrEF therapy should be continued unless there is a compelling reason to stop it.

Pillar 1: ARNI

For many appropriate patients with symptomatic chronic HFrEF, an angiotensin receptor-neprilysin inhibitor (ARNI) is preferred over traditional ACE inhibitor or ARB therapy.

The commonly used ARNI is:

Sacubitril/valsartan

It combines neprilysin inhibition with angiotensin-receptor blockade.

The therapeutic goal is to reduce maladaptive neurohormonal activation while enhancing beneficial natriuretic-peptide pathways.

Why ARNI Matters

ARNI therapy has become foundational because clinical trial evidence demonstrated improved cardiovascular outcomes compared with ACE-inhibitor therapy in appropriate patients with HFrEF.

For the Hospitalist, initiation or transition to ARNI may be considered once the patient is clinically appropriate and hemodynamically stable.

Important considerations include:

Blood pressure
Renal function
Potassium
Previous ACE inhibitor use
History of angioedema
Medication affordability
Ability to obtain outpatient monitoring

Remember that switching from an ACE inhibitor to sacubitril/valsartan requires an appropriate washout period because of angioedema risk.

Pillar 2: Evidence-Based Beta-Blockers

Beta-blockers are another cornerstone of HFrEF treatment.

But not every beta-blocker should be considered interchangeable for this indication.

The three evidence-based beta-blockers commonly emphasized for HFrEF are:

Carvedilol
Metoprolol succinate
Bisoprolol

Beta-blockers reduce harmful sympathetic activation and have demonstrated benefits in appropriately selected patients with HFrEF.

When Should a Beta-Blocker Be Started?

This is particularly important for Hospitalists.

A beta-blocker generally should not be aggressively initiated or titrated while a patient remains significantly decompensated.

Consider the clinical picture:

Is the patient still markedly congested?

Is the patient hypotensive?

Is there cardiogenic shock?

Is IV inotropic support required?

Is perfusion adequate?

Beta-blocker initiation and titration are generally more appropriate after the patient has stabilized and heart failure is compensated.

For a patient already receiving a beta-blocker, the decision to continue, reduce, or temporarily hold therapy depends on the clinical situation.

Pillar 3: Mineralocorticoid Receptor Antagonists

The third major pillar is the mineralocorticoid receptor antagonist, or MRA.

Common examples include:

Spironolactone

and

Eplerenone

MRAs counteract aldosterone-mediated effects that contribute to sodium retention, myocardial fibrosis, and adverse cardiac remodeling.

In appropriate patients with HFrEF, MRAs can reduce morbidity and mortality.

The Hospitalist’s MRA Checklist

Before initiating an MRA, pay particular attention to:

Potassium

Hyperkalemia is an important potential complication.

Kidney Function

Renal function affects both eligibility and monitoring requirements.

Concurrent Medications

Other medications may also increase potassium.

Follow-Up

Patients need appropriate laboratory monitoring after initiation and dose adjustment.

MRAs can be remarkably valuable therapies, but safe prescribing requires reliable follow-up of renal function and electrolytes.

Pillar 4: SGLT2 Inhibitors

Perhaps the biggest change in modern heart-failure treatment has been the arrival of SGLT2 inhibitors.

Examples include:

Dapagliflozin

and

Empagliflozin

These medications were originally developed for diabetes.

But their role now extends far beyond glucose control.

SGLT2 inhibitors have demonstrated important cardiovascular and heart-failure benefits—including in patients who do not have diabetes.

That’s a critical clinical point:

You do not need diabetes to benefit from an SGLT2 inhibitor when it is appropriately indicated for heart failure.

Why Hospitalists Should Pay Attention to SGLT2 Inhibitors

SGLT2 inhibitors have several characteristics that can make them practical components of GDMT.

They generally have:

Minimal blood-pressure lowering compared with some other HF therapies
No requirement for slow dose titration in the way some other GDMT agents require
Heart-failure benefits independent of diabetes status

But clinicians still need to understand important precautions.

These include:

Genital mycotic infections
Volume depletion
Renal-function considerations
Euglycemic diabetic ketoacidosis
Perioperative management
Prolonged fasting or acute critical illness

The medication should be used in the correct clinical context rather than simply added automatically.

The Modern HFrEF Strategy: Don’t Wait Months Between Pillars

One of the most important conceptual changes in HFrEF treatment is speed.

Historically, clinicians might:

Start an ACE inhibitor.

Wait.

Titrate.

Wait again.

Add a beta-blocker.

Titrate for months.

Eventually consider another medication.

That sequential strategy can leave patients without the benefits of other foundational therapies for a prolonged period.

Modern guidance instead favors establishing all four foundational therapies early when feasible, often beginning with low doses and subsequently titrating according to tolerance.

The principle is powerful:

A patient receiving appropriate doses of all four foundational therapies may receive broader benefit than a patient receiving maximally titrated therapy from only one or two classes while the remaining pillars are absent.

The Hospitalization Is an Opportunity

Hospitalists frequently encounter patients admitted with acute decompensated heart failure.

Historically, the inpatient goal sometimes became:

Diurese. Improve oxygenation. Discharge.

But hospitalization provides an opportunity to ask a bigger question:

Is this patient’s chronic heart-failure therapy optimized?

Before discharge, consider reviewing:

ARNI/ACEi/ARB
Evidence-based beta-blocker
MRA
SGLT2 inhibitor
Diuretic requirement
Blood pressure
Renal function
Potassium
Volume status
Medication affordability
Follow-up plan

Not every medication needs to be started in every patient during every hospitalization.

But every hospitalization can be an opportunity to identify why a foundational therapy is missing.

A Practical Hospitalist Approach to HFrEF

Consider a patient admitted with acute decompensated HFrEF.

Step 1: Stabilize the Patient

Address:

Oxygenation
Congestion
Perfusion
Blood pressure
Precipitating factors

Potential triggers may include:

Medication nonadherence
Ischemia
Arrhythmia
Infection
Uncontrolled hypertension
Renal dysfunction
Excess sodium/fluid intake
Medication-related decompensation
Step 2: Achieve Appropriate Decongestion

Loop diuretics remain essential for treating congestion.

But there is an important distinction:

Diuretics improve congestion and symptoms.

They are not substitutes for the foundational disease-modifying therapies that constitute HFrEF GDMT.

The patient may need both.

Step 3: Review Existing GDMT

Ask:

Which of the four pillars is the patient receiving?

For every missing therapy, ask:

Why isn’t this patient receiving it?

Possible answers include:

Hypotension
Hyperkalemia
Renal dysfunction
Previous intolerance
Contraindication
Cost
Access
Lack of follow-up

But sometimes the answer is simply:

Nobody started it yet.

That is a potentially modifiable gap.

Step 4: Start Appropriate Therapies When Stable

Once the patient is hemodynamically stable, clinicians can evaluate opportunities to initiate or optimize GDMT.

The exact sequence should be individualized.

There isn’t one mandatory order that works for every patient.

For example:

Low Blood Pressure?

An MRA or SGLT2 inhibitor may sometimes be easier to introduce than therapies with greater blood-pressure effects.

High Heart Rate?

An evidence-based beta-blocker may become particularly relevant once the patient is compensated.

Hyperkalemia?

MRA and RAAS-inhibiting therapy require careful consideration and monitoring.

Diabetes or CKD?

SGLT2 inhibition may provide benefits extending beyond heart failure, depending on the patient’s clinical situation.

This is why GDMT should be patient-directed, not simply checklist-directed.

Step 5: Don’t Forget the Discharge Plan

Starting medication is only half the job.

The patient also needs a plan for:

Medication access
Laboratory monitoring
Blood-pressure monitoring
Renal-function assessment
Potassium monitoring
Weight monitoring
Diuretic adjustment
Cardiology/heart-failure follow-up
Primary-care follow-up

GDMT optimization often continues after discharge.

Hospitalization should create momentum rather than represent the end of the process.

What About HFpEF?

HFpEF deserves separate consideration because it should not simply be treated as HFrEF with a normal ejection fraction.

Management includes:

Treating congestion
Optimizing blood pressure
Managing atrial fibrillation
Addressing diabetes
Treating obesity
Evaluating sleep apnea
Managing chronic kidney disease
Addressing coronary disease when present

SGLT2 inhibitors have become an important evidence-based therapy for HFpEF.

Depending on the patient, other therapies such as an MRA, ARNI, or ARB may also be considered.

The key point is that the classic four-pillar HFrEF framework should not automatically be applied unchanged to every patient with HFpEF.

What About HFmrEF?

Patients with mildly reduced EF occupy an important middle ground.

SGLT2 inhibitors have particularly strong evidence in this population.

Other HFrEF therapies—including ARNI/ACEi/ARB, evidence-based beta-blockers, and MRAs—may also be considered in appropriately selected patients, particularly toward the lower end of the EF spectrum.

Again, phenotype matters.

Common GDMT Mistakes
Mistake #1: Waiting for the Outpatient Cardiologist

Hospitalists shouldn’t assume every opportunity for optimization must wait until clinic.

When clinically appropriate, hospitalization can be an important opportunity to initiate therapy.

Mistake #2: Maximizing One Drug Before Starting Another

Modern HFrEF management emphasizes establishing the foundational medication classes early rather than spending months maximizing one medication while other pillars remain absent.

Mistake #3: Thinking SGLT2 Inhibitors Are Only Diabetes Drugs

They are now major heart-failure medications.

Mistake #4: Treating the Ejection Fraction Instead of the Patient

Blood pressure, renal function, potassium, heart rate, congestion, perfusion, comorbidities, adherence, affordability, and patient preferences all influence treatment.

Mistake #5: Stopping GDMT Because EF Improved

A patient whose EF improves after HFrEF therapy may still benefit from continuing treatment.

Improved EF should not automatically lead to withdrawal of successful therapy.

The Four-Pillar GDMT Checklist

For a patient with HFrEF, ask:

Pillar 1

ARNI — or ACEi/ARB when appropriate?

Pillar 2

Evidence-based beta-blocker?

Pillar 3

MRA?

Pillar 4

SGLT2 inhibitor?

Then ask:

Is the patient congested?

Is the patient hemodynamically stable?

What is the blood pressure?

What is the heart rate?

What is the potassium?

What is the renal function?

Can the patient afford these medications?

Who will monitor the patient after discharge?

That is where a medication list becomes a real heart-failure treatment strategy.

Frequently Asked Questions About GDMT
What are the four pillars of GDMT for HFrEF?

The four foundational medication classes are an ARNI or appropriate RAAS inhibitor, an evidence-based beta-blocker, an MRA, and an SGLT2 inhibitor.

Should all four medications be started at once?

There is no mandatory sequence for every patient. Current strategies emphasize establishing the four foundational therapies early when feasible, often at low doses, followed by titration according to clinical tolerance.

Which beta-blockers are used for HFrEF?

The evidence-based beta-blockers are carvedilol, metoprolol succinate, and bisoprolol.

Do patients need diabetes to receive an SGLT2 inhibitor for heart failure?

No. The heart-failure benefits of SGLT2 inhibitors extend to appropriately selected patients without diabetes.

Should GDMT be started during hospitalization?

For clinically stable, appropriate patients, hospitalization can be an important opportunity to initiate and optimize GDMT rather than automatically postponing therapy until outpatient follow-up.

Should GDMT continue when the EF improves?

Patients with previous HFrEF whose EF improves above 40% are generally advised to continue HFrEF therapy to reduce the risk of relapse.

Are diuretics part of the four pillars?

No. Loop diuretics are extremely important for treating fluid overload and congestion, but they are not one of the four foundational disease-modifying HFrEF medication classes.

The Bottom Line

Modern HFrEF treatment can be remembered with four foundational pillars:

ARNI/RAAS Inhibition + Beta-Blocker + MRA + SGLT2 Inhibitor

But excellent heart-failure care involves more than remembering four medication classes.

The real skill is knowing:

When to start them.

How to sequence them.

When to titrate them.

When to temporarily hold them.

How renal function and potassium influence decisions.

How to manage low blood pressure.

How to transition from acute decompensation to chronic therapy.

And most importantly:

How to make sure the patient leaves the hospital with a treatment plan that can actually be continued.

For Hospitalists, this is one of the most important opportunities in contemporary Heart Failure care.

Keep Your Hospital Medicine Knowledge Current

Heart Failure management is changing rapidly, and GDMT is only one of many areas where new evidence can influence everyday inpatient practice.

At CME Getaways, continuing education is designed to help physicians and other healthcare professionals stay current with practical topics relevant to modern Hospital Medicine and Internal Medicine.

Review the evidence.

Discuss challenging clinical decisions.

Connect with colleagues.

Then enjoy the destination.

Learn. Connect. Getaway.

Explore upcoming Hospitalist CME and Internal Medicine CME opportunities with CME Getaways.